Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway

Surgery (United States)

Volumn 153, Issue 1, 2013, Pages 4-16

  Chen, Yun ^a,b   Tsai, Ya Hui ^a,b   Tseng, Sheng Hong ^c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b YUAN ZE UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 1; MICRORNA 34A; MYC PROTEIN; PURVALANOL A; ROSCOVITINE; SURVIVIN;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; NERVE CELL NECROSIS; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CDC2 PROTEIN KINASE; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICRORNAS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PURINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84870864690     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2012.03.030     Document Type: Article

References (56)

1. J.R. Park, A. Eggert, and H. Caron Neuroblastoma: biology, prognosis, and treatment Pediatr Clin North Am 55 2008 97 120
2. R. Janardhanan, N.L. Banik, and S.K. Ray N-Myc down regulation induced differentiation, early cell cycle exit, and apoptosis in human malignant neuroblastoma cells having wild type or mutant p53 Biochem Pharmacol 78 2009 1105 1114
3. E.A. Beierle, A. Trujillo, A. Nagaram, E.V. Kurenova, R. Finch, and X. Ma N-MYC regulates focal adhesion kinase expression in human neuroblastoma J Biol Chem 282 2007 12503 12516
4. H. Shimada, I.M. Ambros, L.P. Dehner, J. Hata, V.V. Joshi, and B. Roald The International Neuroblastoma Pathology Classification (the Shimada system) Cancer 86 1999 364 372
5. L.A. Goodman, B.C. Liu, C.J. Thiele, M.L. Schmidt, S.L. Cohn, and J.M. Yamashiro Modulation of N-myc expression alters the invasiveness of neuroblastoma Clin Exp Metastasis 15 1997 130 139
6. A. Goga, D. Yang, A.D. Tward, D.O. Morgan, and J.M. Bishop Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC Nat Med 13 2007 820 827
7. K. Bettayeb, N. Oumata, A. Echalier, Y. Ferandin, J.A. Endicott, and H. Galons CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases Oncogene 27 2008 5797 5807
8. D.O. Morgan Cyclin-dependent kinases: engines, clocks, and microprocessors Annu Rev Cell Dev Biol 13 1997 261 291
9. N.S. Gray, L. Wodicka, A.M. Thunnissen, T.C. Norman, S. Kwon, and F.H. Espinoza Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors Science 281 1998 533 538
10. B. Schutte, L. Nieland, M. van Engeland, M.E. Henfling, L. Meijer, and F.C. Ramaekers The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics Exp Cell Res 236 1997 4 15
11. T. Dohi, E. Beltrami, N.R. Wall, J. Plescia, and D.C. Altieri Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis J Clin Invest 114 2004 1117 1127
12. D.C. Altieri Survivin, versatile modulation of cell division and apoptosis in cancer Oncogene 22 2003 8581 8589
13. J. Song, T. So, M. Cheng, X. Tang, and M. Croft Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion Immunity 22 2005 621 631
14. D.C. Altieri The case for survivin as a regulator of microtubule dynamics and cell-death decisions Curr Opin Cell Biol 18 2006 609 615
15. J. Tran, Z. Master, J.L. Yu, J. Rak, D.J. Dumont, and R.S. Kerbel A role for survivin in chemoresistance of endothelial cells mediated by VEGF Proc Natl Acad Sci U S A 99 2002 4349 4354
16. R. Ito, S. Asami, S. Motohashi, S. Ootsuka, Y. Yamaguchi, and M. Chin Significance of survivin mRNA expression in prognosis of neuroblastoma Biol Pharm Bull 28 2005 565 568
17. V. Gabarra-Niecko, M.D. Schaller, and J.M. Dunty FAK regulates biological processes important for the pathogenesis of cancer Cancer Metastasis Rev 22 2003 359 374
18. N. Bushati, and S.M. Cohen microRNA functions Annu Rev Cell Dev Biol 23 2007 175 205
19. D.P. Bartel MicroRNAs: genomics, biogenesis, mechanism, and function Cell 116 2004 281 297
20. S. Deng, G.A. Calin, C.M. Croce, G. Coukos, and L. Zhang Mechanisms of microRNA deregulation in human cancer Cell Cycle 7 2008 2643 2646
21. W.C. Cho OncomiRs: the discovery and progress of microRNAs in cancers Mol Cancer 6 2007 60
22. C.Z. Chen MicroRNAs as oncogenes and tumor suppressors N Engl J Med 353 2005 1768 1771
23. K.A. Cole, E.F. Attiyeh, Y.P. Mosse, M.J. Laquaglia, S.J. Diskin, and G.M. Brodeur A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene Mol Cancer Res 6 2008 735 742
24. J.H. Schulte, S. Horn, S. Schlierf, A. Schramm, L.C. Heukamp, and H. Christiansen MicroRNAs in the pathogenesis of neuroblastoma Cancer Lett 274 2009 10 15
25. J.S. Wei, Y.K. Song, S. Durinck, Q.R. Chen, A.T. Cheuk, and P. Tsang The MYCN oncogene is a direct target of miR-34a Oncogene 27 2008 5204 5213
26. J.H. Schulte, S. Horn, T. Otto, B. Samans, L.C. Heukamp, and U.C. Eilers MYCN regulates oncogenic MicroRNAs in neuroblastoma Int J Cancer 122 2008 699 704
27. L. Fontana, M.E. Fiori, S. Albini, L. Cifaldi, S. Giovinazzi, and M. Forloni Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM PLoS One 3 2008 e2236
28. V. Ciccarone, B.A. Spengler, M.B. Meyers, J.L. Biedler, and R.A. Ross Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages Cancer Res 49 1989 219 225
29. C.J. Thiele Neuroblastoma cell lines J. Masters, Human cell culture Vol 1 1998 Kluwer Academic Publishers Lancaster, UK 21 53
30. P. Obexer, J. Hagenbuchner, T. Unterkircher, N. Sachsenmaier, C. Seifarth, and G. Bock Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis Mol Biol Cell 20 2009 2041 2048
31. Y. Suenaga, Y. Kaneko, D. Matsumoto, M.S. Hossain, T. Ozaki, and A. Nakagawara Positive auto-regulation of MYCN in human neuroblastoma Biochem Biophys Res Commun 390 2009 21 26
32. X. Wang A PCR-based platform for microRNA expression profiling studies RNA 15 2009 716 723
33. W.A. Weiss, K. Aldape, G. Mohapatra, B.G. Feuerstein, and J.M. Bishop Targeted expression of MYCN causes neuroblastoma in transgenic mice EMBO J 16 1997 2985 2995
34. T. Otto, S. Horn, M. Brockmann, U. Eilers, L. Schüttrumpf, and N. Popov Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma Cancer Cell 15 2009 67 78
35. J.D. Walton, D.R. Kattan, S.K. Thomas, B.A. Spengler, H.F. Guo, and J.L. Biedler Characteristics of stem cells from human neuroblastoma cell lines and in tumors Neoplasia 6 2004 838 845
36. J.J. Molenaar, M.E. Ebus, D. Geerts, J. Koster, F. Lamers, and L.J. Valentijn Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells Proc Natl Acad Sci U S A 106 2009 12968 12973
37. L.M. Hansford, W.D. Thomas, J.M. Keating, C.A. Burkhart, A.E. Peaston, and M.D. Norris Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification Proc Natl Acad Sci U S A 101 2004 12664 12669
38. S.L. Cohn, W.B. London, D. Huang, H.M. Katzenstein, H.R. Salwen, and T. Reinhart MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN J Clin Oncol 18 2000 3604 3613
39. E. Beltrami, J. Plescia, J.C. Wilkinson, C.S. Duckett, and D.C. Altieri Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis J Biol Chem 279 2004 2077 2084
40. M. Mesri, N.R. Wall, J. Li, R.W. Kim, and D.C. Altieri Cancer gene therapy using a survivin mutant adenovirus J Clin Invest 108 2001 981 990
41. Y. Wakamatsu, Y. Watanabe, H. Nakamura, and H. Kondoh Regulation of the neural crest cell fate by N-myc: promotion of ventral migration and neuronal differentiation Development 124 1997 1953 1962
42. W.C. Gustafson, and W.A. Weiss Myc proteins as therapeutic targets Oncogene 29 2010 1249 1259
43. N. Cosgrave, A.D. Hill, and L.S. Young Growth factor-dependent regulation of survivin by c-myc in human breast cancer J Mol Endocrinol 37 2006 377 390
44. A.J. Alvi, B. Austen, V.J. Weston, C. Fegan, D. MacCallum, and A. Gianella-Borradori A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival Blood 105 2005 4484 4491
45. A. Bonni, A. Brunet, A.E. West, S.R. Datta, M.A. Takasu, and M.E. Greenberg Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms Science 286 1999 1358 1362
46. D. Iizuka, O. Inanami, I. Kashiwakura, and M. Kuwabara Purvalanol A enhances cell killing by inhibiting up-regulation of CDC2 kinase activity in tumor cells irradiated with high doses of X rays Radiat Res 167 2007 563 571
47. D. Iizuka, A. Ogura, M. Kuwabara, and O. Inanami Purvalanol A induces apoptosis and downregulation of antiapoptotic proteins through abrogation of phosphorylation of JAK2/STAT3 and RNA polymerase II Anticancer Drugs 19 2008 565 572
48. E.A. Monaco 3rd, C.M. Beaman-Hall, A. Mathur, and M.L. Vallano Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons Biochem Pharmacol 67 2004 1947 1964
49. J. Houseley, and D. Tollervey The many pathways of RNA degradation Cell 136 2009 763 776
50. Y. Li, F. Guessous, Y. Zhang, C. Dipierro, B. Kefas, and E. Johnson MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes Cancer Res 69 2009 7569 7576
51. Q. Ji, X. Hao, M. Zhang, W. Tang, M. Yang, and L. Li MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells PLoS One 4 2009 e6816
52. Y. Chen, X. Zhu, X. Zhang, B. Liu, and L. Huang Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy Mol Ther 18 2010 1650 1656
53. C. Welch, Y. Chen, and R.L. Stallings MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells Oncogene 26 2007 5017 5022
54. L. Meijer, and E. Raymond Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials Acc Chem Res 36 2003 417 425
55. F.I. Raynaud, S.R. Whittaker, P.M. Fischer, S. McClue, M.I. Walton, and S.E. Barrie In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202 Clin Cancer Res 11 2005 4875 4887
56. C. Benson, J. White, J. De Bono, A. O'Donnell, F. Raynaud, and C. Cruickshank A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days Br J Cancer 96 2007 29 37